Prolia gets TGA tick
October 2, 2013
Amgen Australia and
GlaxoSmithKline have welcomed
TGA approval of a new indication
for Prolia (denosumab), the only
Australian approved RANK Ligand
inhibitor for men with osteoporosis
at increased risk of fracture.
Prolia has already been
recommended to be listed on the
PBS for men with a minimal trauma
fracture, or men aged 70 or over
with a BMD T-score of -2.5 or less.
“Osteoporosis and osteoporosisrelated
fractures are commonly
associated with postmenopausal
women with few recognising that
the condition can affect men,” said
Professor Peter Ebeling, Head of
Endocrinology, Western Health.
“In reality, one in three Australian
men over the age of 60 will suffer
from an osteoporosis related
fracture, and for those who do
suffer an osteoporosis induced
fracture, their life expectancy
is more likely to be reduced
compared with women,” he said.
Prolia is administered twice yearly
as an injection.
The above article was sent to subscribers in Pharmacy Daily's issue from 02 Oct 13To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Oct 13
